Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

Novo Nordisk (NVO) has reportedly been criticized by a U.K. pharma industry group for mischaracterizing certain payments to ...

We recently compiled a list of the 8 Best Socially Responsible Stocks to Buy According to Hedge Funds. In this article, we ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

UBS analyst upgraded Novo Nordisk (NVO) to Buy from Neutral with ... treatment that could still show differentiation in type 2 diabetes. UBS is a buyer of weakness and says shares are at an ...

Novo Nordisk is doubling down on its collaboration ... focus to cover Novo’s defining indications—obesity and Type 2 diabetes—and increases the program cap to 20. If the programs hit their ...

(Reuters) - Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health ... and develop up to 20 new treatments for obesity, type 2 diabetes, and cardiovascular diseases. Under the terms of ...

Novo Nordisk provided significant funding to UK pharmacies for training, advertising and patient resources ... Compounding For Its Early-Generation Diabetes Drug Between 2021 and 2023, Novo ...

rendering these products less effective or ineffective for conditions such as type 2 diabetes, cardiovascular disease, and chronic weight management. Novo Nordisk also noted 44 documented adverse ...

Let's find out. Novo Nordisk has been making breakthroughs in diabetes care for about 100 years. The company is still at it. As of August 2024, it had a 33.9% share of the diabetes care market ...

Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of drugs that are allowed to be compounded. In a Citizen Petition posted on ...